CAMRF News and Press, Camurus AB

2023-12-20 00:16:06 ET Summary With the significant treatment gap, Indivior is well positioned for growth as more patients receive treatment for Opioid Use Disorder. Sublocade, the first FDA-approved buprenorphine LAI for OUD, has seen impressive growth but faces competition from ...

The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence PR Newswire LUND, Sweden , May 3, 2021 /PRNewswire/ -- Camurus AB (NASDAQ STO: CAMX) today announced that the Australian regulatory agency, the Therapeutic Good...

Camurus ([[CAMRF]]) announces that the Committee for Medicinal Products for Human Use ((CHMP)) of the European Medicines Agency's ((EMA)) has issued a positive opinion recommending marketing authorization for a new, 160mg, monthly dose of Buvidal (buprenorphine) prolonged release in...

Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence PR Newswire LUND, Sweden , March 26, 2021 /PRNewswire/ -- Camurus today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Eu...

Once-weekly formulation of setmelanotide achieved weight loss efficacy comparable to daily-dosing formulation Both weekly and daily formulations of setmelanotide were observed to be safe and well-tolerated LUND, Sweden , June 24, 2020 /PRNewswire/ --  Camurus' partner Rhyt...

Camurus ( OTC:CAMRF ) has increased FY2020 net revenue guidance to SEK340M - SEK380M from SEK290M - SEK330M with estimated product sales of SEK310M - SEK340M from SEK240M - SEK280M, driven by increasing market shares of Buvidal for treatment of opioid dependence in Europe and Australi...

LUND, Sweden , June 23, 2020 /PRNewswire/ --  Camurus today announced revised full year 2020 guidance for the company's revenue and product sales. Camurus' guidance for net revenue is increased to SEK 340 -380 million from SEK 290 -330 million with estimated product sales of SEK 3...

LUND, Sweden , June 1, 2020 /PRNewswire/ -- Camurus AB (NASDAQ: CAMX) (STO: CAMX) today announces that the company's US partner Braeburn has submitted a request for final approval of Brixadi™ (buprenorphine) weekly and monthly extended release injection for the treatment of op...

STOCKHOLM , May 7, 2020 /PRNewswire/ -- "The number of patients treated with Buvidal® increased by 90 percent in the quarter" Summary first quarter 2020             Total revenues of SEK 49.3 million (18.5), an increas...

Large increase in the number of patients treated with weekly and monthly Buvidal ®  for opioid dependence Camurus reiterates its 2020 outlook, with sales and total revenues expected to reach the higher end of previous guidance   Lund, Sweden , April 2, 2020 /PRNews...